Manasi A. Tirodkar, PhD, MS

Quality Outlook

Oncology Quality Measurement: Angst and Ambition

09/18/2019

In the first installment of the Quality Outlook commentary series, Tom Valuck, MD, JD, Discern Health, part of Real Chemistry, and colleagues assert the need for value-based solutions and adequate value assessment measurements to ensure that...

In the first installment of the...

09/18/2019

Journal of Clinical Pathways

Quality Outlook

We Need Better Quality Measures for Oncology Care First

01/24/2020

Manasi A. Tirodkar , PhD, MS;

David Blaisdell , BA;

Tom Valuck , MD, JD;

Tom Valuck, MD, JD, and colleagues of Discern Health, part of Real Chemistry, argue that if the Oncology Care First model proposed by CMS is adopted as proposed, CMS will be missing a critical opportunity to advance quality measurement for...

Tom Valuck, MD, JD, and...

01/24/2020

Journal of Clinical Pathways

Quality Outlook

Sound Check: Listening More Closely to Oncology Patients

03/24/2020

Manasi A. Tirodkar , PhD, MS;

David Blaisdell , BA;

Tom Valuck , MD, JD;

Theresa Schmidt , MA, PMP, CSPO;

Tom Valuck, MD, JD, and colleagues explore whether patient-reported measure sets and patient-reported performance measures truly represent oncology patients’ feedback and needs.

Tom Valuck, MD, JD, and...

03/24/2020

Journal of Clinical Pathways